Researchers in Japan have developed a new antibody treatment, named H2Mab-250, aimed at fighting HER2-positive breast cancer, a type of cancer characterized by high levels of the HER2 protein on cancer cells.
Unlike existing treatments such as trastuzumab, which can affect both cancerous and normal cells, H2Mab-250 is designed to specifically target and attach only to the cancer cells, leaving healthy cells unharmed.
The team’s experiments showed that H2Mab-250 works similarly to trastuzumab in reducing tumor growth in mice implanted with human breast cancer cells, despite H2Mab-250 having a weaker ability to bind to HER2 and activate immune cells to kill the cancer.
This suggests that H2Mab-250 might be a valuable option for breast cancer treatment, potentially offering effective cancer targeting with fewer side effects.
The researchers also discussed how the unique properties of H2Mab-250 could be advantageous in developing new cancer treatments like CAR-T cell therapies, which are a type of treatment that modifies a patient’s own immune cells to fight cancer.
H2Mab-250 appears to be a promising new antibody that specifically targets breast cancer cells overexpressing HER2 without affecting normal cells, potentially offering a safer treatment option.
Further research is needed to fully understand its benefits and how it can be used in cancer therapy.
